论文部分内容阅读
目的:探讨在体外不同浓度的过氧化物酶体增殖物激活受体γ(PPARγ)激动剂罗格列酮(ROZ)对人胃癌细胞系SGC7901的生长及细胞周期的影响。方法:采用MTT法比色实验、集落形成实验、电子显微镜,透射电镜,流式细胞仪分别观察不同浓度罗格列酮0.08μmol/L,0.4μmol/L,2μmol/L,10μmol/L,50μmol/L,作用于SGC7901细胞,对细胞增殖,细胞形态和细胞周期的影响。结果:ROZ可抑制SGC7901细胞的生长以及SGC7901细胞集落的形成,并呈现剂量依赖性,其半数抑制浓度(IC50)约为50μmol/L。透射电镜低倍镜以及高倍下可见凋亡细胞。流式细胞仪结果显示,ROZ可抑制SGC7901细胞,引起G0/G1期细胞大量增加,S期细胞减少,且细胞周期停滞于G1期。结论:ROZ具有抗肿瘤作用,能够抑制SGC7901细胞的增殖并诱导凋亡,这种作用与其诱导细胞周期G0/G1期的停滞和诱导凋亡作用有关。因此,ROZ有望成为胃癌治疗的辅助用药亦或治疗药,PPARγ有潜力成为肿瘤治疗的新靶点。
AIM: To investigate the effects of rosiglitazone (ROZ), a peroxisome proliferator-activated receptor γ (PPARγ) agonist, on the growth and cell cycle of human gastric cancer cell line SGC7901 in vitro. Methods: MTT colorimetric assay, colony formation assay, electron microscopy, transmission electron microscopy and flow cytometry were used to observe the effects of different concentrations of rosiglitazone 0.08μmol / L, 0.4μmol / L, 2μmol / L, 10μmol / L, 50μmol / L, the role of SGC7901 cells on cell proliferation, cell morphology and cell cycle. Results: ROZ inhibited the growth of SGC7901 cells and the formation of colonies of SGC7901 cells in a dose-dependent manner. The IC50 of ROZ was about 50 μmol / L. Transmission electron microscope low magnification and high apoptotic cells can be seen. Flow cytometry showed that ROZ inhibited SGC7901 cells, caused a large increase in G0 / G1 phase cells, S phase cells decreased, and the cell cycle arrest in G1 phase. CONCLUSION: ROZ has anti-tumor effect, can inhibit SGC7901 cell proliferation and induce apoptosis, which is related to its role in arresting and inducing apoptosis in G0 / G1 phase of cell cycle. Therefore, ROZ is expected to become an adjuvant or therapeutic drug for the treatment of gastric cancer, and PPARγ has the potential to become a new target for cancer treatment.